Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-132 in Relapsing-Remitting Multiple Sclerosis
NCT03551275Phase 1Completed
- Sponsor
- BIOCAD
- Start
- Feb 2018
- Primary completion
- Oct 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Divozilimab in relapsing-remitting multiple sclerosis (RRMS) (4 cohorts), sponsored by BIOCAD. Primary endpoints: Adverse Events and Serious Adverse Events at Day 169, CTCAE Grade 3-4 Adverse Events at Day 169 and 2 more. Started Feb 2018; status: completed.
02
Drugs
Divozilimab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03551275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03551275.